Navigation Links
Elekta's Monaco System Used for First Time to Create VMAT Plan for Delivery on Varian Treatment System
Date:11/9/2012

PORTLAND, Ore., Nov. 9, 2012 /PRNewswire/ -- The Department of Radiation Medicine at Oregon Health & Science University's (OHSU) Knight Cancer Institute was first to treat a cancer patient using Elekta's Monaco® software to create a Volumetric Modulated Arc Therapy (VMAT) treatment plan and then deliver it on a Varian Trilogy® treatment machine.  Prior to this first clinical use combining Monaco VMAT and Trilogy, OHSU physicists had produced Monaco test plans using prior treatment data from 15 patients, the plans for which had been generated using their customary planning system.

The Monaco test plans compared favorably to the clinical plans in three crucial aspects, said Wolfram Laub, Ph.D., M.B.A., chief physicist for the OHSU Knight Cancer Institute's radiation medicine department and clinical associate professor at OHSU.

"First, Monaco uses the XVMC Monte Carlo dose engine, which is considered the gold standard for dose calculation," he said. "Comparing the Monaco plans to those produced by our usual planning system, I noticed higher volumes of normal tissues exposed to low radiation dose levels, which I attribute to the fact that Monte Carlo can more accurately account for photon scatter."

Dr. Laub, who serves as a consultant for Elekta, believes that the Monaco treatment plans tend to be less complex in terms of the shape of IMRT segments, when producing the same quality plans. QA passing rates on average have been observed to be higher. "Less complexity is always better as long as it doesn't impact plan quality," he said.

The third observation regarding the Monaco plans applies to the advantages of using biological constraints. "I believe that biological constraints give a great deal of control over a treatment plan. They allow the use of templates, or what I call a 'class solution,' which is not possible to the same extent when dosimetrists use DVH constraints for optimization – since those really need to be tailored for each patient."

The latest version of Monaco (v.3.20) features the new Segment Shape Optimization™ tool, which drives improved dose conformity, plan quality and delivery efficiency, he added.

The OHSU Knight Cancer Institute's radiation oncology team has already begun treating a second cancer patient using the Monaco VMAT/Trilogy combination.

Monaco works seamlessly with ARIA OIS
Dr. Laub also has found that Monaco is compatible with Varian's ARIA® oncology information system (OIS) as well. 

The typical workflow entails sending the CT simulation scan to their existing planning system, which is used for contouring. The contours and CT scan are subsequently exported from the planning system into Monaco.

"We then run the optimization in Monaco, import everything back into ARIA for record-and-verify, and that's where the plan gets approved and sent to the treatment machine," he explains. "It's pretty seamless, actually."

Learn more about Monaco at www.elekta.com/rtp.

For further information, please contact:
Johan Andersson Melbi, Investor Relations Manager, Elekta AB
Tel: +46 702 100 451, email: johan.anderssonmelbi@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Springer to publish new open access journal with the Korean Society for Micro and Nano Systems
2. Aushon BioSystems and AH diagnostics unterzeichnen Distributionsvertrag für Skandinavien
3. HealthTech Capital Announces Awards for the HealthTech Conference 2012 - Building a Business in the New HealthTech Ecosystem
4. Aushon BioSystems and AH diagnostics Sign Distribution Deal for Scandinavia
5. C8 MediSensors Gains CE Mark Approval for the C8 MediSensors Optical Glucose Monitor(TM) System for People with Diabetes
6. AyoxxA Biosystems Closes Series A Financing Round
7. WaferGen Bio-systems Awarded 1 Million Euro Grant by the Luxembourg Government to expand its European Operations
8. University of California, San Francisco (UCSF) Selects Conflict of Interest Management System
9. Medical Marijuana, Inc. Portfolio Company PhytoSPHERE Systems Announces Successful Production of Hemp Harvesting for High Value CBD Oil
10. Millions of DNA switches that power human genomes operating system are discovered
11. Aushon BioSystems Appoints Martin Verhoef Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... of drug and device development, and Prism Clinical Research , a leader ... announced Verified Clinical Trials (VCT) has been selected by both companies ...
(Date:1/18/2017)... ... January 18, 2017 , ... Opal Kelly, a ... or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed ... business-card sized form factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... Clinical Ops Executives 2017 in its continued commitment to the advancement of the ... to discuss current issues related to clinical trial planning and management. , ...
(Date:1/18/2017)... ... January 18, 2017 , ... Researchers from a new study are stating ... low enough after prostate cancer treatment, this indicates there is still remaining prostate cancer cells ... , “ The PSA test has always been an indicator of whether a man’s prostate ...
Breaking Biology Technology:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
(Date:12/15/2016)... -- ... Research and Markets has announced the addition of the "Global Military ... report forecasts the global military biometrics market to grow at a CAGR ... been prepared based on an in-depth market analysis with inputs from industry ... the coming years. The report also includes a discussion of the key ...
Breaking Biology News(10 mins):